<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043043</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069498</org_study_id>
    <secondary_id>NCI-02-C-0194</secondary_id>
    <nct_id>NCT00043043</nct_id>
    <nct_alias>NCT00056615</nct_alias>
  </id_info>
  <brief_title>Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia</brief_title>
  <official_title>Rectal Abberant Crypt Foci And Other Intermediate Biomarkers For Sporadic Colorectal Neoplasia: Cross-Sectional Prevelance And Modulation By Celecoxib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may be effective in preventing colorectal cancer in patients who have a&#xD;
      history of rectal polyps or colorectal neoplasia.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing&#xD;
      colorectal cancer in patients who have a history of rectal polyps or colorectal neoplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the effects of celecoxib vs placebo on the number of rectal aberrant crypt foci&#xD;
           in patients with premalignant rectal polyps or prior sporadic colorectal neoplasia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the effects of these drugs on proliferation index, apoptotic index, and gene&#xD;
           expression patterns in ascending and descending colon tissue from these patients before&#xD;
           and after treatment.&#xD;
&#xD;
        -  Assess gene expression patterns in normal mucosa from the ascending vs descending colon&#xD;
           in patients referred for screening, surveillance, or diagnostic colonoscopy.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, chemoprevention study.&#xD;
      Patients are stratified according to age (18 to 49 vs 50 and over) and number of rectal&#xD;
      aberrant crypt foci (5-9 vs 10 or more).&#xD;
&#xD;
      All patients undergo a baseline biomarker assessment and full colonoscopy to resect all&#xD;
      neoplasms, quantitate rectal aberrant crypt foci, and biopsy rectal mucosa.&#xD;
&#xD;
      Depending on the results of the biomarker assessments, patients are randomized to 1 of 2&#xD;
      treatment arms. Patients with no adenomas of 5 mm or greater receive no further treatment.&#xD;
&#xD;
        -  Arm I: Patients receive oral celecoxib twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for&#xD;
           6 months in the absence of unacceptable toxicity.&#xD;
&#xD;
      All patients undergo an endoscopic exam of the colorectum at completion of study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients will be accrued for the baseline biomarker&#xD;
      assessment and a total of 40 patients (20 per arm) will be accrued for the chemoprevention&#xD;
      study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Age 18 to 49 with one of the following colorectal abnormalities:&#xD;
&#xD;
               -  At least one adenoma that is at least 1 cm&#xD;
&#xD;
               -  At least 3 adenomas of any size with at least 5 rectal aberrant crypt foci (ACFs)&#xD;
&#xD;
          -  Age 50 and over with one of the following colorectal abnormalities:&#xD;
&#xD;
               -  At least one adenoma that is at least 5 mm and at least 5 rectal ACFs&#xD;
&#xD;
               -  History of polyps (at least 1 adenoma) within the past 5 years&#xD;
&#xD;
          -  No history of germline cancer syndrome&#xD;
&#xD;
          -  No stage III or IV colorectal cancer (Dukes' C or D) diagnosed within the past 6&#xD;
             months&#xD;
&#xD;
          -  No current colorectal cancer&#xD;
&#xD;
          -  No inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin greater than 11.5 g/dL&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 125,000/mm^3&#xD;
&#xD;
          -  No significant bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 1.5 times ULN&#xD;
&#xD;
          -  No chronic or acute hepatic disorder&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No chronic or acute renal disorder&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No asthma&#xD;
&#xD;
          -  No severe chronic obstructive pulmonary disease&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No active gastrointestinal ulcers&#xD;
&#xD;
          -  No history of peptic ulcer disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior hypersensitivity reaction to NSAIDs, aspirin, or sulfa drugs&#xD;
&#xD;
          -  No medical contraindication to NSAID use&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use effective contraception&#xD;
&#xD;
          -  No known allergic reaction to indigo carmine&#xD;
&#xD;
          -  No other clinically significant medical condition or abnormal laboratory value that&#xD;
             would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Anticipated use of corticosteroids less than 2 weeks over 6 months&#xD;
&#xD;
          -  Anticipated use of mometasone less than 4 weeks over 6 months&#xD;
&#xD;
               -  No other concurrent inhaled steroids for 30 days before or during study&#xD;
                  participation&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
&#xD;
          -  No prior participation in this study&#xD;
&#xD;
          -  No regular nonsteroidal anti-inflammatory drug (NSAID) or aspirin use (average of 3 or&#xD;
             more doses per week for at least 3 months) except low-dose aspirin for cardiovascular&#xD;
             disease prophylaxis&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent fluconazole or lithium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest Hawk</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Naval Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2004</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

